



ASX ANNOUNCEMENT

14 February 2022

CardieX Announces New Clinical Trial with Andwin Scientific, Syneos Health and Philip Morris

Highlights:

- **New Clinical Trial Services Agreement for the provision of ATCOR XCEL devices and data management services;**
- **Trial is to be conducted with Andwin Scientific, Syneos Health and sponsored by Philip Morris;**
- **Total revenue recognition for CardieX is US\$936,000 (~AU\$1,300,000) over a 19-month period with a majority to fall in FY22;**
- **Study is currently to cover 22 sites across the globe.**

CardieX Limited (ASX: CDX) (**CardieX**, the **Company**) is pleased to announce that CardieX subsidiary ATCOR has entered into a new global Clinical Trial Services Agreement (“the Agreement”) with Andwin Scientific, to support companies Syneos Health and cigarette and tobacco manufacturer, Philip Morris, for both the lease of ATCOR XCEL devices and the provision of data management services for a new global clinical trial sponsored by Philip Morris.

The Company’s ATCOR XCEL device is to be used in multiple endpoints for the trial including determination of clinically relevant arterial health outcomes based on aortic augmentation index (AIx) and arterial stiffness - key biomarkers of arterial health that are identified using the ATCOR XCEL device.

Key details of the signed Agreement, which is in immediate effect, are:

- ATCOR is an equipment supplier to Andwin Scientific to provide ATCOR XCEL devices (leasing) and the provision of data management services for the trial.
- Phillip Morris is the sponsor of the trial while Syneos is the Clinical Research Organization (“CRO”). Syneos as the CRO will run and manage the trial and Andwin Scientific will provide the equipment procurement function for the trial on behalf of Syneos.
- Andwin has issued the first purchase order to ATCOR under the the Agreement.
- Currently the total revenue is likely to be ~US\$936,000 (~AU\$1,300,000) over a 19-month period with the majority to be recognised in FY22.



- The “Term” is for the length of the trial. Currently the study is for 19 months across 22 sites, with that term based on expectations of the time required to enrol the subjects, conduct the study and analyse the results.

Any extension in the length of the trial or expansion in the number of sites will be beneficial to CardieX and will result in an increase in services and revenue.

- The Company will advise the market once it has confirmed the registered details of the trial from Andwin.

About the ATCOR XCEL Device

ATCOR’s XCEL device is the only FDA-cleared device for non-invasively measuring central aortic waveforms and reporting on associated clinical data in all adult subjects. XCEL is used by clinicians, research institutions, and leading pharmaceutical companies in monitoring critical hemodynamic data during patient treatment and drug trials in multiple clinical settings and for multiple disease states.

Craig Cooper, CEO & Managing Director commented:

“We continue to see validation of our industry-leading SphygmoCor® technology globally with multiple on-going clinical trials relying on our XCEL device for advanced medical grade arterial health parameters. It’s this same technology that also powers our next generation of devices and partnerships with the upcoming Mobvoi smartwatch, as well as multiple new proposed devices in development for 2022”.

Approved by the Board of Directors and Released by Jarrod White, Director and CFO.

For more information, please contact:

Investor Relations - Australia

Rod Hinchcliffe

rod.hinchcliffe@mcpartners.com.au

Media Relations - Australia

Melissa Hamilton

melissa.hamilton@mcpartners.com

Investor Relations - USA

[Matt Selinger](#)

[Managing Director](#)

[Integrus Communications](#)

mselinger@integcom.com



About CardieX

CardieX is a global health technology company. Its ACTOR subsidiary is a world leader in medical devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders. Its CONNEQT subsidiary develops and markets consumer home health devices and wearables. CardieX is listed on the Australian Stock Exchange (ASX:CDX).

About Andwin Scientific

Established in 1950, Andwin Scientific specializes in outsourced clinical research supply chain and laboratory supplies management to global life science organizations, providing a single source for study supplies & equipment and custom clinical trial & specimen kitting requirements. Andwin's core business focuses on supplies and equipment product manufacturing, sourcing, procurement, storage and distribution as a supplier to global life science organizations and a distributor to direct end using companies. For more information, please visit www.andwinski.com.